Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Protomer

Biotech & Life Sciences · Pasadena, United States · Founded 2014 Unicorn

Glucose-responsive protein therapeutics for automated diabetes management

Valuation
$1–2.5B
Latest valuation · 2026
Unlock exact value
Headcount
<100
Current team size
Unlock exact value

Investors

2 investors on Protomer's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 2 investors entered at this stage
Eli Lilly
JDRF T1D Fund

Global footprint

Where Protomer has talent and traffic

Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown
Web traffic by country
1.6K monthly visits
across markets
🇺🇸 United States100%
Top 1 markets shown

Patent intelligence

$971k patent portfolio · 17 active families

Estimated portfolio value
$971k
0.10% of valuation · 7295.2× smaller than top peer Janssen Vaccines ($7.1B)
17 active patent families
Where Protomer innovates Insulin analogPharmaceutical SubstancesPharmaceutical drugBasal bolusBlood lipids

Where Protomer concentrates vs peers

Each axis is a top-10 topic across Protomer and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Protomer

An AI-synthesized read of the highest-engagement posts about Protomer on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Protomer on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.